Compare TG Therapeutics Inc (TGTX) vs Ishares Msci Thailand Etf (THD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Ishares Msci Thailand Etf — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Ishares Msci Thailand Etf trades at $74.77. The key difference: Ishares Msci Thailand Etf is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | THD | |
|---|---|---|
Market Cap | $8.53B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $59.06 | $75.06 |
52-Week Low | $26.94 | $57.86 |
Enterprise Value | $8.74B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
THD trades at $75.06, up 2.28% with a bearish technical signal from moving averages. The stock shows neutral oscillator readings but faces selling pressure per ADX indicators. Recent news highlights THD's 38% annual returns driven by AI hardware exposure, though this creates vulnerability to profit-taking. Support levels cluster around $71-72 with resistance at $72-73.
Outlook remains cautious due to technical weakness and concentrated AI dependency. The dividend scheduled for June 2026 provides income support, but investors face rotation risks from Asian equities and Thailand's economic sensitivity to regional flows. Valuation metrics remain undisclosed in current data.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →
